Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Domenico Russo, Michael Henry Schmitt, Sylvain Pilorge, Matthias Stelljes, Toshiro Kawakita, Valerie Teal, Barbara Haber, Charlene Bopp, Sanjeet Dadwal, Cyrus Badshah
Topics & Concepts
MedicinePlaceboInternal medicineCytomegalovirusTransplantationHematopoietic stem cell transplantationClinical endpointClinical trialRandomized controlled trialImmunologyViral diseaseHuman immunodeficiency virus (HIV)HerpesviridaePathologyAlternative medicineCytomegalovirus and herpesvirus researchTransplantation: Methods and OutcomesImmunodeficiency and Autoimmune Disorders